-
1.
Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
Witkowska-Patena, E, Giżewska, A, Dziuk, M, Miśko, J, Budzyńska, A, Walęcka-Mazur, A
Clinical nuclear medicine. 2019;(12):e629-e633
Abstract
PURPOSE OF THE REPORT The aim of the study was to prospectively compare performance of F-fluorocholine (FCH) and F-prostate-specific membrane antigen (PSMA)-1007 PET/CT in patients with biochemical relapse (BCR) of prostate cancer and low prostate-specific antigen levels. METHODS We prospectively enrolled 40 BCR patients after radical treatment and prostate-specific antigen levels 2.0 ng/mL or less. F-FCH and F-PSMA-1007 PET/CT imaging was performed within a mean interval of 54 ± 21 days. Scans were done 87 ± 10 and 95 ± 12 minutes after injecting 248 ± 35 and 295 ± 14 MBq of F-FCH and F-PSMA-1007, respectively. Rates of negative, equivocal, and positive scan results were compared per patient. Per lesion, findings were grouped as equivocal or highly suggestive of malignancy and then compared for their number, localization (local relapse, lymph nodes, bones), and SUVmax values. RESULTS Positive, equivocal, and negative results were reported in 60%, 27.5%, and 12.5% of F-PSMA-1007 and in 5%, 37.5%, and 57.5% of F-FCH scans, respectively. In 70% of scans, F-PSMA-1007 PET/CT upgraded F-FCH PET/CT results. F-PSMA-1007 scans also showed significantly more lesions (184 vs 63, P = 0.0006). Local relapse, lymph node, and bone lesions accounted, respectively, for 9%, 58%, and 33% of F-PSMA-1007 and 5%, 89%, and 6% F-FCH of PET/CT findings. Highly suspicious lesions accounted for 74% of F-PSMA-1007 and 11% of F-FCH PET/CT findings. In F-PSMA-1007 PET/CT SUVmax values of highly suggestive lesions were significantly higher than in equivocal lesions (median, 3.6 vs 2.5; P < 0.00001). CONCLUSIONS In early BCR patients F-PSMA-1007 showed a higher detection rate than F-FCH PET/CT. The former also showed more lesions in total, more highly suggestive lesions and less equivocal lesions.
-
2.
Tetracycline, nicotinamide, and lesionally administered clobetasol as a therapeutic option to prednisone in patients with bullous pemphigoid: a comparative, retrospective analysis of 106 patients with long-term follow-up.
Kalinska-Bienias, A, Kowalczyk, E, Jagielski, P, Kowalewski, C, Wozniak, K
International journal of dermatology. 2019;(2):172-177
Abstract
BACKGROUND Bullous pemphigoid (BP) is an autoimmune blistering disease associated with preexisting comorbidities and higher mortality. The interest in using therapy other than oral steroids in BP management results from severe complications and increased risk of death. The efficacy of oral doxycycline or whole-body application of topical clobetasol has been proven in randomized controlled trials. The case series study suggested that combination of tetracycline, nicotinamide, and lesionally administered clobetasol may also be useful. METHODS We conducted a clinical 3-year retrospective study of treatment with tetracycline, nicotinamide, and lesionally administered clobetasol (TNC) in comparison to prednisone (P). Out of 106 patients (mean age 78 ± 9.9 years) with newly diagnosed BP, 59 received tetracycline 1.5 g/daily, nicotinamide 1.2 g/daily, and 0.05% lesionally administered clobetasol cream, and 47 patients - prednisone 0.5 mg/kg daily. RESULTS The median time to disease control was achieved after 7 days in both groups. At 4 weeks, 93.2% of patients treated with TNC and 89.1% from P group achieved disease control. The median period between complete remission and relapse was 60 days in the TNC group and 90 days in the P group (P = 0.84). At least one relapse within 1 year was noted in 32.1% of patients from the TNC group and 50% from the P group (P = 0.09). The 1-year survival for the TNC and P groups was 83% and 65.9%, respectively (P = 0.04), and the 3-year survival was 71.2% and 48% (P = 0.019), respectively. CONCLUSIONS Tetracycline and nicotinamide combined with lesionally administered clobetasol is an alternative, effective treatment with better survival rates compared to prednisone in BP.
-
3.
Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.
Giesel, FL, Will, L, Lawal, I, Lengana, T, Kratochwil, C, Vorster, M, Neels, O, Reyneke, F, Haberkon, U, Kopka, K, et al
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018;(7):1076-1080
Abstract
The introduction of 18F-labeled prostate-specific membrane antigen (PSMA)-targeted PET/CT tracers, first 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) and more recently 18F-PSMA-1007 (((3S,10S,14S)-1-(4-(((S)-4-carboxy-2-((S)-4-carboxy-2-(6-18F-fluoronicotinamido)butanamido)butanamido)methyl)phenyl)-3-(naphthalen-2-ylmethyl)-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid)), have demonstrated promising results for the diagnostic workup of prostate cancer. This clinical study presents an intraindividual comparison to evaluate tracer-specific characteristics of 18F-DCFPyL versus 18F-PSMA-1007. Methods: Twelve prostate cancer patients, drug-naïve or before surgery, received similar activities of about 250 MBq of 18F-DCFPyL and 18F-PSMA-1007 48 h apart and were imaged 2 h after injection on the same PET/CT scanner using the same reconstruction algorithm. Normal-organ biodistribution and tumor uptake were quantified using SUVmaxResults: PSMA-positive lesions were detected in 12 of 12 prostate cancer patients. Both tracers, 18F-DCFPyL and 18F-PSMA-1007, detected the same lesions. No statistical significance could be observed when comparing the SUVmax of 18F-DCFPyL and 18F-PSMA-1007 for local tumor, lymph node metastases, and bone metastases. With regard to normal organs, 18F-DCFPyL had statistically significant higher uptake in kidneys, urinary bladder, and lacrimal gland. Vice versa, significantly higher uptake of 18F-PSMA-1007 in muscle, submandibular and sublingual gland, spleen, pancreas, liver, and gallbladder was observed. Conclusion: Excellent imaging quality was achieved with both 18F-DCFPyL and 18F-PSMA-1007, resulting in identical clinical findings for the evaluated routine situations. Nonurinary excretion of 18F-PSMA-1007 might present some advantage with regard to delineation of local recurrence or pelvic lymph node metastasis in selected patients; the lower hepatic background might favor 18F-DCFPyL in late stages, when rare cases of liver metastases can occur.
-
4.
[An effect of cytoprotective therapy on stress resistance and compensatory abilities of patients with chronic cerebral ischemia].
Antipenko, EA, Derugina, AV, Gustov, AV
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015;(12):74-78
Abstract
OBJECTIVE To study an effect of nonspecific cytoprotective therapy on clinical manifestations, disease course and indicators of stress system in patients with different stages of chronic cerebral ischemia (CCI). MATERIAL AND METHODS Authors examined 266 patients with CCI, aged from 35 to 55 years. The patients received basic and nonspecific cytoprotective therapy. The dynamics of subjective and objective symptoms of encephalopathy, clinical outcomes after a year of observation, and the state of stress system were analyzed. An effect of therapy on stress was assessed by the dynamics of blood pressure reactions to stress. RESULTS AND CONCLUSION An open randomized comparative study has shown that the inclusion of the drug with nonspecific cytoprotective actions (cytoflavin) in the therapeutic complex improves the therapeutic effect on the clinical manifestations of CCI. The higher frequency of favorable outcomes over one year of follow-up is associated with the optimization of stress system activity under nonspecific cytoprotective therapy and the increase in stress resistance.
-
5.
[Event-related potentials in moderate cognitive impairment in patients with chronic cerebral ischemia treated with cytoflavin].
Madzhidova, EN, Khaĭdarova, DK, Khodzhaeva, DT
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;(8):42-5
Abstract
Authors compared cognitive functions in 60 patients (main group) with different stages of discirculatory encephalopathy (DE), I, II and III stages. A comparison group included 10 age-matched normals without DE. All patients underwent a clinical-neurological investigation and performed neuropsychological tests (MMSE, the Clock drawing test, Burdon probe) and Spilberger-Khanin test. Cognitive evoked potentials, including P300, were recorded. Results revealed the decrease in performance on neuropsychological tests and P300 components that indicated the slowing of metabolic processes in the cerebral cells of patients with DE. In patients treated with cytoflavin, the activation of metabolic processes in the brain cells that indicated the protection of the cellular cluster clinically manifested itself in neurocognitive and electrophysiological improvements was observed.
-
6.
Topical 4% nicotinamide vs. 1% clindamycin in moderate inflammatory acne vulgaris.
Khodaeiani, E, Fouladi, RF, Amirnia, M, Saeidi, M, Karimi, ER
International journal of dermatology. 2013;(8):999-1004
Abstract
Nicotinamide and clindamycin gels are two popular topical medications for acne vulgaris. This study aimed to compare efficacy of the topical 4% nicotinamide and 1% clindamycin gels in these patients. In this randomized, double-blind clinical trial, patients with moderate inflammatory facial acne vulgaris were randomly allocated to receive either topical 4% nicotinamide (n = 40) or 1% clindamycin gels (n = 40) twice daily. In each group, they were further categorized in two subgroups with oily and non-oily types of facial skin. The Cook's acne grade was determined at baseline and at weeks 4 and 8 post treatment. Acne grade decreased from an average of 5.93 ± 0.83 at baseline to 4.03 ± 1.33 at week 4 and 2.08 ± 1.59 at week 8 in nicotinamide receivers, and from an average of 5.70 ± 0.94 at baseline to 3.85 ± 1.66 at week 4 and 2.03 ± 1.53 at week 8 in the clindamycin group (within-group P < 0.001, between-group P > 0.05). Comparing with each other, nicotinamide and clindamycin gels were significantly more efficacious in oily and non-oily skin types, respectively. No major side effect was encountered by any patient. Skin type is a significant factor in choosing between topical nicotinamide and clindamycin in patients with acne vulgaris.
-
7.
[Cytoflavin in the detoxification of alcohol-dependent patients].
Minko, AI, Linskiĭ, IV, Kuz'minov, VN, Samoĭlova, ES, Goloshchapov, VV, Artemchuk, KA
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;(6):35-40
Abstract
Cytoflavin was used in the complex detoxification of 30 alcohol-dependent patients and 30 patients of the comparison group who did not receive this drug. It has been shown that cytoflavin promotes the regression of alcohol withdrawal symptoms, including arterial hypertension, tachycardia, nausea, vomiting, hyperhydrosis, tremor, the severity of head and headache. At the same time, cytoflavin significantly reduces the total score on the CIWA-Ar scale and severity of an autonomic component of pathological alcohol craving to the fifth day of treatment. It has been concluded that cytoflavin is effective and safe for the complex detoxification of alcohol-dependent patients.
-
8.
[Correction of energy homeostasis in the acute period of concomitant brain injury].
Nikonov, VV, Pavlenko, AIu, Beletskiĭ, AV
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;(7):32-6
Abstract
A randomized prospective study of 191 patients with concomitant brain injury (CBI) of different severity has been carried out. All patients underwent surgery and received treatment in reanimation and intensive care departments. The main group consisted of 100 (52.4%) patients treated with cytoflavin in dosage 20-40 ml daily intravenously in drops during 10 days in addition to standard treatment. The comparison group included 91 (47.6%) patients who received standard treatment only. A positive effect of cytoflavin on clinical symptoms and laboratory characteristics of patients with CBI was identified. The decrease in severity measured with the APACHE II, higher activation of consciousness and improvement in the dynamics of neurological symptoms in these patients have resulted in the reduction in the duration of artificial lung ventilation and total hospital stay.
-
9.
[Cytoflavin in the treatment of patients with chronic abacterial prostatitis and erectile dysfunction].
Churakov, AA, Kolesnikov, AI, Bliumberg, BI, Popkov, VM
Urologiia (Moscow, Russia : 1999). 2012;(5):64-6, 68
Abstract
The problem of chronic prostatitis (CP) and erectile dysfunction (ED) involves not only their high prevalence, but also the insufficient effectiveness of their treatments. In this regard, there is need for administration the pathogenetic drugs with antihypoxic, antioxidant and neuroprotective effects and improving blood flow to the genitals. The study included 60 men with CP associated with ED, aged 22 to 60 years. Patients were randomized into 2 groups of 30 people. Patients of comparison group received baseline therapy (alpha1-adrenoblockers, non-specific anti-inflammatory drugs, digital prostate massage and vacuum phallostimulation). Antibiotics were applied on the basis of their potential effectiveness in chronic abacterial prostatitis. In addition to the above treatment, patients of main group received step-down therapy with cytoflavin (in infusion, then oral administration). Positive dynamics was noted in both groups of patients; however, according to the indicators of the severity of pain and dysuria, as well as quality of life, positive dynamics in the main group of patients was more significant. Similarly, the dynamics of objective criteria for inflammation in the prostate gland was more pronounced when using cytoflavin. After treatment, the rigid phase of erection during vacuum fallotest occurred within 2-3 min from the beginning of the procedure in 16 (53.3%) patients of main group and only in 9 (30%) patients of comparison group. During follow-up examination at 6 months after treatment, stable remission was found in 75% of patients of main group. Thus, the inclusion of cytoflavin in the scheme of complex treatment of patients with abacterial CP associated with ED is pathogenetically justified, makes it more efficient and provides good DFS.
-
10.
[Postoperative correction of the methabolism of the single lung after pulmonectomy].
Iakovlev, AIu, Gordeeva, OS, Denisenko, AN, Vorontsov, AIu, Ulitin, DN
Khirurgiia. 2011;(4):47-50